[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340745-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340745-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrated-proteomics-and-scrna-seq-analyses-of-ovarian-cancer-reveal-molecular-subtype-associated-cell-landscapes-and-immunotherapy-targets","Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets","","Epithelial ovarian cancer remains highly lethal, and current understanding of how molecular subtypes connect to therapeutic options is incomplete. This study integrates mass spectrometry-based proteomics of 154 tumor samples and 29 normal fallopian tubes with single-cell RNA sequencing from additional EOC tumors to define proteomic subtypes. Four subtypes show distinct clinical relevance, including immune-infiltrating features linked to CD40 and CD40RL+ IL17R CD4+ T-cell interactions, and a TYMP inhibitor strategy for non-immune patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrated-proteomics-and-scrna-seq-analyses-of-ovarian-cancer-reveal-molecular-subtype-associated-cell-landscapes-and-immunotherapy-targets/340745/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrated-proteomics-and-scrna-seq-analyses-of-ovarian-cancer-reveal-molecular-subtype-associated-cell-landscapes-and-immunotherapy-targets/340745.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were proteomic and single-cell datasets used in this study?","Question",{"text":63,"@type":64},"Mass spectrometry-based proteomics profiled 154 EOC tumor samples and 29 normal fallopian tubes, while single-cell RNA sequencing was performed on additional EOC tumors. The combined analyses were used to define proteomic subtypes and characterize cellular ecosystems and clinical significance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the four proteomic subtypes identified?",{"text":68,"@type":64},"The study identifies four proteomic subtypes: malignant proliferative (C1), immune infiltrating (C2), Fallopian-like (C3), and differentiated (C4). Each subtype shows distinct clinical relevance.",{"name":70,"@type":61,"acceptedAnswer":71},"Which findings link immune features to prognosis and therapy?",{"text":72,"@type":64},"The C2 subtype is characterized by lymphocyte infiltration, increased GZMK CD8+ T cells, and phagocytosis-like MRC+ macrophages. CD40 is reported as a specific prognostic factor for C2, and interactions between CD40+ phagocytosis-like macrophages and CD40RL+ IL17R CD4+ T cells correlate with favorable prognosis. TYMP inhibition is validated as a promising strategy for non-immune patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340745,1790319861,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE OPEN   \nMolecular Diagnostics  \nIntegrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets  \nRong Tan 1,2,3,4,5,14 ✉, Ming Wen1,2,3,4,5,14, Wenqing Yang 1,4,6, Dongdong Zhan7,8, Nairen Zheng7, Mingwei Liu7, Fang Zhu1,6, Xiaodan Chen1,6, Meng Wang2,3, Siyu Yang1,6, Bin Xie9,10, Qiongqiong He9,10, Kai Yuan4,11, Lunquan Sun2,3,4,11,12, Yi Wang7 ✉, Jun Qin7,13 ✉ and Yu Zhang 1,4,6 ✉  \n© The Author(s) 2024  \n\n|  | BACKGROUND: Epithelial ovarian cancer (EOC) represents the most lethal gynaecological malignancy, yet understanding the connections between its molecular subtypes and their therapeutic implications remains incomplete.\u003Cbr>METHODS: We conducted mass spectrometry-based proteomics analyses of 154 EOC tumour samples and 29 normal fallopian tubes, and single-cell RNA sequencing (scRNA-seq) analyses of an additional eight EOC tumours to classify proteomic subtypes and assess their cellular ecosystems and clinical signiﬁcance. The efﬁcacy of identiﬁed therapeutic targets was evaluated in patientderived xenograft (PDX) and orthotopic mouse models.\u003Cbr>RESULTS: We identiﬁed four proteomic subtypes with distinct clinical relevance: malignant proliferative (C1), immune inﬁltrating (C2), Fallopian-like (C3) and differentiated (C4) subtypes. C2 subtype was characterized by lymphocyte inﬁltration, notably an increased presence of GZMK CD8+ T cells and phagocytosis-like MRC+ macrophages. Additionally, we identiﬁed CD40 as a speciﬁc prognostic factor for C2 subtype. The interaction between CD40+ phagocytosis-like macrophages and CD40RL+ IL17R CD4+ T cells was correlated with a favourable prognosis. Finally, we established a druggable landscape for non-immune EOC patients and veriﬁed a TYMP inhibitor as a promising therapeutic strategy.\u003Cbr>CONCLUSIONS: Our study reﬁnes the current immune subtype for EOC, highlighting CD40 agonists as promising therapies for |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| C2 subtype patients and targeting TYMP for non-immune patients. |  |  |\n|  | British Journal of Cancer (2025) 132:111–125; [https://doi.org/10.1038/s41416-024-02894-2](https://doi.org/10.1038/s41416-024-02894-2) |  |\n|  |  |  |\n\nBACKGROUND  \nEpithelial ovarian cancer (EOC), presenting the highest mortality rate among gynaecological malignant tumours, constitutes approximately 85% to 90% of ovarian cancer malignancies. Due to the absence of symptoms in the early stages and a lack of appropriate diagnostic methods, 70% to 80% of patients are diagnosed at an advanced stage, characterized by widespread metastasis in the abdominal cavity. Unfortunately, only 31% of women diagnosed with distant invasive EOC survive for 5 years [1]. The low survival rate of advanced EOC primarily results from its  \nhigh recurrence rate and eventual development of diffuse dissemination and chemo-resistance.  \nA multi-platform analysis of stage III-IV high-grade serous carcinomas (HGSCs) performed by The Cancer Genome Atlas (TCGA) identiﬁed four molecular subtypes characterized by‘immunoreactive’, ‘differentiated’, ‘proliferative’, and ‘mesenchymal’ signatures [2] . Additionally, a mass spectrometry-based proteomics analysis by the Clinical Proteomic Tumour Analysis Consortium (CPTAC) revealed classiﬁcations highly consistent with transcriptome-based clusters [3]. The CPTAC study also identiﬁed a  \n1Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, China. 2Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China. 3Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha, China. 4National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. 5Hunan key laboratory of agi","cbCaiaQ3XDkpUMlT","https://ap.wps.com/l/cbCaiaQ3XDkpUMlT","pdf",2809189,15,"English","# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"How were proteomic and single-cell datasets used in this study?\",\"answer\":\"Mass spectrometry-based proteomics profiled 154 EOC tumor samples and 29 normal fallopian tubes, while single-cell RNA sequencing was performed on additional EOC tumors. The combined analyses were used to define proteomic subtypes and characterize cellular ecosystems and clinical significance.\"},{\"question\":\"What are the four proteomic subtypes identified?\",\"answer\":\"The study identifies four proteomic subtypes: malignant proliferative (C1), immune infiltrating (C2), Fallopian-like (C3), and differentiated (C4). Each subtype shows distinct clinical relevance.\"},{\"question\":\"Which findings link immune features to prognosis and therapy?\",\"answer\":\"The C2 subtype is characterized by lymphocyte infiltration, increased GZMK CD8+ T cells, and phagocytosis-like MRC+ macrophages. CD40 is reported as a specific prognostic factor for C2, and interactions between CD40+ phagocytosis-like macrophages and CD40RL+ IL17R CD4+ T cells correlate with favorable prognosis. TYMP inhibition is validated as a promising strategy for non-immune patients.\"}]","Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets | PDF",1790038630,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/741f865df1183a2ed77853dd0168479b.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02120bc595783ac954fd9a0f8236dca8.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d158115aa0f61928f4e0c83353cf6530.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13d8b9ce1ea3508c142949a4856bc010.webp",980,1301]